Skip to content

Role and mechanism of inflammatory factor IL-3 in promoting diabetic foot healing by Transverse Tibial Bone Movement (TTBM)

Role and mechanism of inflammatory factor IL-3 in promoting diabetic foot healing by Transverse Tibial Bone Movement (TTBM)

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900026077
Enrollment
Unknown
Registered
2019-09-20
Start date
2019-09-18
Completion date
Unknown
Last updated
2019-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic foot ulcer

Interventions

Group1:Transverse Tibial Bone Movement(TTBM)

Sponsors

Taizhou Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 years or older; 2. Diagnosed as diabetes, diagnosed as diabetic foot; 3. Female patients capable of bearing children must test negative for pregnancy and must use an acceptable method of birth control; 4. Blood glucose control, HbA1c 0.5; 6. Ulcer area between 2 and 25 cm2; 7. Routine blood and blood chemistry values as follows: Pre-albumin levels of >= 15 mg/dL; Alanine aminotransferase (ALT) 8.0 g/dL; WBC > 2.0 x 10^9/L; Absolute neutrophil count > 1.0 x 10^9/L; Platelet count > 50 x 10^9/L.

Exclusion criteria

Exclusion criteria: 1. High risk of anesthesia or surgery; 2. Ulcers caused by electrical, chemical, or radiation burns; 3. Currently pregnant or breastfeeding; 4. Lacked cooperation and poor treatment compliance; 5. Received cancer surveillance or anti-tumor treatment in the past five years; 6. Mental illness were not treated; 7. VTE during the first 3 months of the study; 8. Chronic diseases are worsening; 9. Typical Charcot 's foot; 10. Acute or chronic hepatitis, cirrhosis, serum albumin <2.0 GMS/dL, or alkaline phosphatase , LDH with twice the upper limit of the normal range; 11. Acquired Immunodeficiency Syndrome (AIDS) or is infected with Human Immunodeficiency Virus (HIV); 12. Any symptoms that seriously impair the completion of the study.

Design outcomes

Primary

MeasureTime frame
CRP;IL-3;

Secondary

MeasureTime frame
Quality of Life;Record of adverse events;

Countries

China

Contacts

Public ContactDun Hong

Taizhou Hospital

hongdun@aliyun.com+86 13586123889

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026